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Despite the progress of conventional vaccines, improvements are clearly required due to
concerns about the weak immunogenicity of these vaccines, intrinsic instability in vivo,
toxicity, and the need for multiple administrations. To overcome such problems, nano-
technology platforms have recently been incorporated into vaccine development.
Nanocarrier-based delivery systems offer an opportunity to enhance the humoral and
cellular immune responses. This advantage is attributable to the nanoscale particle size,
which facilitates uptake by phagocytic cells, the gut-associated lymphoid tissue, and the
mucosa-associated lymphoid tissue, leading to efficient antigen recognition and presen-
tation. Modifying the surfaces of nanocarriers with a variety of targeting moieties permits
the delivery of antigens to specific cell surface receptors, thereby stimulating specific and
selective immune responses. In this review, we introduce recent advances in nanocarrier-
based vaccine delivery systems, with a focus on the types of carriers, including liposomes,
emulsions, polymer-based particles, and carbon-based nanomaterials. We describe the
remaining challenges and possible breakthroughs, including the development of needle-
free nanotechnologies and a fundamental understanding of the in vivo behavior and sta-
bility of the nanocarriers in nanotechnology-based delivery systems.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
The seasonal outbreaks of pantropic infection diseases have
elevated the development of effective vaccines to the status of
a global healthcare concern. Vaccines have been developed
using killed organisms [1], live attenuated organisms [2], or
inactivated toxins [3]. Recently, subunit vaccines [4], and DNAfax: þ82 2 882 2493.
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University. Production an
ns.org/licenses/by-nc-ndvaccines that encode antigenic pathogenic proteins [5] have
been examined as new vaccine modalities. Although subunit
vaccines and DNA vaccines have the advantages of a high
safety profile over traditional vaccine, these vaccines suffer
from a relatively lower immunogenicity. The immunogenicity
may potentially be improved by modulating the vaccine
formulation using nanotechnology.h).
sity.
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Fig. 1 e Structure of nanocarriers for vaccine antigen
delivery. (A) Liposomes, (B) emulsions, (C) polymeric
nanoparticles, and (D) graphene oxide nanosheets.
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vaccines encompass nanocarriers having a variety of com-
positions, sizes, and surface properties [6]. Numerous vaccine
nanocarriers have been designed and investigated for their
utility in the delivery of antigens and adjuvants to immune
cells in an effort to promote a protective immune response.
Unfortunately, although antigens may be taken up by the
immune cells, insufficient adjuvant activity may result in
limited immunogenicity. In some approaches, nanocarriers
have been designed to co-deliver both an antigen and an
adjuvant [7]. Nanocarriers can facilitate the targeting and/or
sustained release of antigens or adjuvants to antigen-
presenting cells [8,9].
Working mechanisms of nanotechnology-based vaccine
formulations support the utility of nanocarriers in the vaccine
fields. Particles smaller than 10 mm are readily taken up by
phagocytic cells, such as macrophages and dendritic cells
(DC). This property has been used to improve the cellular
uptake of antigens, thereby increasing the efficiency of anti-
gen recognition and presentation [10]. Solid nanocarriers can
protect protein-based antigen vaccines from degradation and
facilitate entry into the gut-associated lymphoid tissue and
mucosa-associated lymphoid tissues, rendering them appro-
priate for vaccine delivery via oral or mucosal routes [11].
Surface-modified nanocarriers may assist the targeted de-
livery of antigens. Immune cells express a variety of surface
receptors, including the mannose receptor, scavenger recep-
tor, and toll-like receptors (TLR) [12]. Nanocarriers coated with
immune cell-targeting molecules, such as carbohydrates [13],
antibodies [14], and peptides [15], may target these overex-
pressed receptors to improve the efficiency of antigen and
adjuvant delivery toward the promotion of specific and se-
lective immune responses in prophylactic vaccines.
This review provides an overview of recent advances in
nanocarrier vaccine systems, including liposomes, emulsions,
polymer-based nanodelivery systems, and carbon-based
nanodelivery systems (Fig. 1). The current status of in vivo
applications of nanocarriers is summarized in Table 1.2. Nanodelivery systems for vaccines
2.1. Liposomes
Since the first report that liposomes can act as immunological
adjuvants [16], liposome formulations (Fig. 1A) have been
extensively studied for use in vaccine delivery systems. As of
this publication, at least 8 liposomal vaccines are in clinical
trials or have been approved for human use [17]. The physi-
cochemical properties of liposomes, including their size, lipid
composition, and structure, may be modulated according to
the properties of the vaccine antigen to maximize immuno-
genicity. Liposomes are composed of biocompatible phospho-
lipid bilayers and are capable of loading and delivering both
hydrophilic and hydrophobic molecules. These properties
enable the co-delivery of antigen and othermolecules, such as
adjuvants. The surfaces of liposomes may be easily modified
using the appropriate functionally active lipid as a component
of the lipid bilayer. Surface-modified liposomes have been
designed to target immune cells, co-deliverimmunostimulatory agents, and enhance both the humoral
and cell-mediated immune responses simultaneously to
improve the efficacy of liposomal vaccines.
The physicochemical properties of liposomes, such as their
size and fluidity, are important for the induction of an im-
mune response. The vesicle sizes of liposomes composed of
cationic dimethyldioctadecylammonium (DDA) can affect the
cell-mediated immune response, but not the humoral im-
mune response [18]. Liposomes larger than 2 mm in diameter
were found to effectively promote interleukin-10 production,
whereas liposomes 500 nm in diameter promoted a higher
level of interferon-g production in splenocytes.
Small unilamellar vesicles composed of cationic DDA li-
posomes were found to produce higher CD8 T cell responses
compared to the larger multilamellar vesicles [19]. A recent
study reported that rigid DDA lipid-based liposomes produced
a Th1-directed immune response against antigens that was
100 times greater than the response produced by fluidic
dimethyldioleoylammonium (DODA)-based liposomes [20].
The liposomal delivery of protein antigens via surface
adsorption methods may be optimized by tuning the surface
antigen and lipid ratio. The protein surface antigen-to-lipid
ratio can affect the aggregation behavior of liposomes and
can impact general vaccine stability during storage [21]. Sur-
face modifications to antigen-carrying liposomes gearing
polyethylene glycol (PEG) groups can reduce liposome aggre-
gation. However, the retention of the liposomes at the injec-
tion sites was simultaneously reduced, thereby altering the
Th1/Th2 immune response compared to the response pro-
duced by unmodified liposomes [22].
The liposomal co-delivery of antigens and an immunosti-
mulatory molecule can enhance the generation of a protective
immuneresponse.Theentrapmentof trehalose6,6-dibehenate
(TDB), an immunostimulatorymolecule, within a liposome did
not affect thephysicochemical properties of neutral distearoyl-
sn-glycero-3-phosphocholine (DSPC) or cationic DDA-based li-
posomes, and significantly increased the production of IFN-g
after immunization [23]. Monophosphoryl lipid A (MPL), a
poorly soluble TLR 4 agonist, was added to the bilayers of
Table 1 e In vivo applications of nanocarriers for delivery of vaccines.
Delivery system Composition Antigen Route References
Liposome DDA, TDB Ag85B-ESAT-6 Intramuscular [18]
DDA, TDB OVA Intramuscular [19]
DDA, DODA, TDB Ag85B-ESAT-6 Intramuscular [20]
Pegylated DDA, TDB Ag85B-ESAT-6 Subcutaneous [22]
DDA, DSPC, cholesterol, TDB Ag85B-ESAT-6 Subcutaneous [23]
MPL, DDA, TDB OVA Intraperitoneal [24]
DDA, TDB Trivalent influenza vaccine Subcutaneous [25]
DOPC, DOPG, MPB OVA Subcutaneous [26]
EPC, DOGS-NTA-Ni His-tagged heat shock protein Intradermal [27]
MDMPC, DMPG, cholesterol, MPL Polyhistidinylated OVA Subcutaneous [28]
Lecithin, cholesterol Diphtheria toxoid Subcutaneous [29]
Emulsion MF59 Hemagglutinin Intramuscular [34]
MF59 Recombinant meningococcal B protein Intramuscular [36]
MF59 Recombinant meningococcal B protein Intramuscular [35]
W805EC OVA Intranasal [39]
W805EC OVA Intranasal [40]
GLA Falciparum subunit Subcutaneous [41]
GLA-SE Plasmodium vivax subunit Subcutaneous [42]




PLGA OVA Subcutaneous [8]
PLGA, polylactic acid Hepatitis B surface antigen Pulmonary [45]
Lipid-coated PLGA OVA Subcutaneous [46]
Lipid-coated PLGA Malaria antigen Subcutaneous [47]
Chitosan-coated polycaprolactone H1N1 hemagglutinin Intranasal [48]
Polyanhydrides Yersinia pestis antigen Intranasal [49]
Polylactic acid Hepatitis B surface antigen Subcutaneous [51]
Deacylated cationic polyethyleneimine HIV CN54gp140 antigen Pulmonary [52]
PEGylated poly [2-(N,N-dimethylamino)
rthylmethacrylate]




N-trimethyl chitosan OVA Intranasal [54]
Chitosan nanoparticles HBsAg Intraperitoneal [56]
Cholesteryl-conjugated pullulan Clostridium botulinum type-A neurotoxin
subunit antigen
Intranasal [57]
Carbon-based system SWCNT Tuberculin purified protein derivative Subcutaneous [59]
Carbon nanotube Azoxystrobin Subcutaneous
Intraperitoneal
[60]
Carbon magnetic nanoparticles Hen egg lysozyme Intravenous [61]
Carbon nanoparticles Bovine serum albumin Oral [63]
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liposome membrane packing and reduce the surface charges.
The MPL/DDA/TDB liposomal formulation carried ovalbumin
(OVA) as a model antigen. In mice, the presence of MPL in
liposomes did not affect the humoral immune response, but
significantly enhanced the antigen-specific CD8þ T cell im-
mune response [24]. Some studies reported the use of an adju-
vant formulation comprising liposomes containing an
immunostimulatory molecule. The co-administration of a
trivalent influenza vaccine and cationic liposomes containing
TDB was found to augment both the humoral and the cellular
immune responses [25].
Interbilayer-crosslinked multilamellar vesicles were
recently designed and tested as nanocarriers for protein anti-
gens [26]. The vesicles were formed by crosslinking the head
groups of lipid bilayers within anionic mutilamellar vesicles
composedof1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-di-(9Z-octadecenoyl)-snglycero-3-phospho-(1'-rac-glycerol)
(DOPG) and maleimide-headgroup lipid 1,2-dioleoyl-sn-glyc-
ero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) butyr-
amide (MPB). Interbilayer crosslinking via divalent magnesium
cation-based fusion permitted the stable entrapment ofprotein antigens within the core and lipophilic immunostimu-
latorymoleculeswithin the lipidmembranes. OVAwas used as
a model antigen to demonstrate that the interbilayer-
crosslinked vesicles provided the sustained release of antigens
and enhanced the antigen-specific CD8þ T cell immune
response in comparison with the uncrosslinked liposomes.
Nickel-chelating liposomes were examined for their po-
tential use in His-tag-mediated antigen vaccine loading [27].
Nickel-chelating liposomes 100 nm in size were prepared
using egg phosphatidylcholine (EPC) and a nickel-chelating
lipid, 1,2-dioleoyl-sn-glycero-3-[N(5-amino-1-carboxypentyl)
iminodiacetic acid] succinyl nickel salt (DOGS-NTA-Ni), in a
molar ratio of 95:5. The His-tagged heat shock protein from
Candida albicans was loaded onto the surfaces of the nickel-
chelating liposomes via the formation of metallochelating
bonds by incubating the antigens with the liposomes.
Nickel-chelating liposomes have also been prepared by
incorporating nitrilotriacetic acid lipid derivatives into the
liposomes to promote bonding to polyhistidinylated OVA
antigens [28]. The liposomes were composed of DOGS-NTA-
Ni, dimyristoylphosphatidylcholine (DMPC), dimyr-
istoylphosphatidylglycerol (DMPG), cholesterol, and MPL.
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ful progress toward recombinant protein antigen loading
without covalently modifying the antigens, the toxicity of
the nickel-chelating lipids presents certain safety concerns
for clinical applications.
Liposomes-in-oil adjuvant formulations were found to
prolong the immune response after vaccination [29]. Diph-
theria toxoids were co-encapsulated with poly (I:C) in a lipo-
some composed of lecithin and cholesterol (9:1 M ratio). The
subcutaneous injection of the liposomes suspended in oil
(Marcol 52:Montanide 888, 9:1) generated a persistent immune
response by reducing antigen transport to the draining lymph
nodes.
Cationic liposomes have been examined for their ability to
enhance the adjuvanticity of nucleic acid-based TLR agonists.
Liposomes composed of the cationic lipid octadecenolyoxy
[ethyl-2-heptadecenyl-3 hydroxyethyl] imidazolinium chlo-
ride and cholesterol were complexed to the TLR agonist CpG-
based plasmid DNA [30]. The intramuscular administration of
the combination of lipoplexes and Fluzone, an influenza
vaccine, was shown to provide an enhanced antibody
response and cell immunity in mice [30] and in elderly rhesus
macaques [31].2.2. Emulsions
Emulsions have been long studied as adjuvant formulations
and more recently studied as vaccine delivery systems.
Emulsions are dispersions of two or more immiscible liquids
composed of oil, emulsifiers, and excipients (Fig. 1B). Two
broad classes of emulsions may be formed: water-in-oil
emulsions and oil-in-water emulsions. The latter emulsion
type is typically used in adjuvant formulations.
Themost famous vaccine adjuvant emulsion isMF59.MF59
consists of squalene oil, Span 85, and Tween 80 in a citrate
buffer. The MF59-adjuvanted seasonal flu vaccine (Fluad™)
was approved in Europe in 1997 [32]. MF59 can effectively in-
crease the immune response in infants and young children
[33]. A recent study investigated the role of each component of
MF59 toward the adjuvant properties [34]. Span 85 was found
to activate the muscle transcriptome. However, Span 85 alone
did not provide an efficient immune response comparable to
that of MF59.
MF59was studied for its ability to augment the induction of
antibodies against meningococcal protein antigens [35] and
the Neisseria meningitidis B vaccine [36]. The delivery of re-
combinant meningococcal B protein antigens in conjunction
with the TLR4 agonist, E6020, withinMF59was shown to cause
a strong antigen-specific CD4 T-cell response after three
staged intramuscular injections into CD-1 mice [35].
AF03, another squalene-based emulsion, has beenused as a
vaccine adjuvant. AF03, which consists of squalene, sorbitan
oleate, and cetheareth-12, is present in themarketed influenza
vaccine,Humenza™. Recently, thephysicochemical properties
of AF03 were characterized to evaluate the long-term stability
of the formulation. The surfactants in AF03 were analyzed
using mass spectroscopy and high-performance liquid
chromatography-mass spectroscopy as quality control tests in
emulsionmanufacturing processes [37,38].In addition to the squalene-based MF59 and AF03 emul-
sions, adjuvant nanoemulsion formulations have been
developed without squalene. For example, an aqueous
dispersion of W805EC, composed of cetyl pyridinium chloride,
Tween 80, ethanol, and soybean oil, in phosphate-buffered
saline or 0.9% NaCl was found to promote an immune
response to the model antigen OVA via intranasal adminis-
tration [39]. The nasal adjuvanticity of the W805EC nano-
emulsion was attributed to dendritic cell engulfment of
antigen-loaded epithelial cells [40].
Glucopyranosyl lipid A (GLA), a TLR4 agonist, has been
tested for its adjuvanticity in the context of oil-in-water
emulsion vaccine antigen formulations. For example, GMZ2,
a fusion protein component in an anti-falciparum vaccine,
was combined with GLA in an oil-in-water emulsion vaccine
formulation [41]. The immunostimulatory properties of GLA
were then compared with the properties of several other
immunostimulatory agents formulated with GMZ2. GLA was
found to display the highest antigen-specific IgG2a and total
IgG titers. Another study reported that the immunogenicity of
a recombinant Plasmodium vivax protein vaccine could be
enhanced by subcutaneously co-delivering the vaccine with
GLA in an oil-in-water emulsion formulation [42]. The intra-
dermal administration of GLA within oil-in-water emulsions
to human skin explants was found to enhance the capacity of
skin DCs to activate both CD4þ T cells and the emigration of
Langerhans cells within skin tissues [43]. Oil-in-water emul-
sions containing GLA and recombinant hemagglutinin are
currently in phase 2 clinical trials for the prevention of sea-
sonal influenza [44]. The adjuvanticity of the hemagglutinin
emulsion prepared with GLA was found to increase the titers
of hemagglutinin-specific antibodies relative to the formula-
tion prepared without GLA, following intramuscular admin-
istration to healthy adults.
The successful commercialization of squalene-based
emulsions in marketed vaccines suggests that emulsion adju-
vant approaches warrant further exploration. Formulation
stability during storage and the development of biocompatible
oil componentsmaybecrucial concerns for thedevelopmentof
new emulsion formulations for vaccine delivery.
2.3. Synthetic polymer-based nanodelivery systems
Polymeric nanocarriers (Fig. 1C) have been examined as vac-
cine delivery systems to take advantage of their ability to offer
the controlled release of antigens or adjuvants. Poly(lactic-co-
glycolic acid) (PLGA) is the most widely used biodegradable
synthetic polymer nanocarrier with a relatively long history of
biomedical use. The PLGA particle size has been varied and
surface modifications have been introduced into vaccine for-
mulations for use in oral, mucosal, and systemic delivery.
The sizes, surface modification, and release profiles of
PLGA particles were shown to affect the immunogenicity of
entrapped antigens. The average size of an aerosolized PLGA
or poly(L-lactic acid)-based nanoparticle pulmonary hepatitis
B virus vaccine formulation was suggested to influence the
immunogenicity of the antigen [45]. Nanoparticles larger than
500 nm induced the generation of antigen-specific secretary
IgA more effectively than smaller nanoparticles (<500 nm) in
rats.
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modified with lipids to enable the co-delivery of antigens and
adjuvants [46]. In a recent study the OVA antigen was cova-
lently anchored to a pegylated phospholipid bilayer coating
formedonthePLGAnanoparticlesurfaces,anda lipidadjuvant,
suchasMPLora-galactosylceramide,was incorporated intothe
lipid bilayer. Subcutaneous co-delivery of OVAwithMPL in the
surface lipid coating of PLGA nanoparticles was shown to
enhance the antigen-specific IgG titer values more than 10
folds. Other groups have conjugated a candidate P. vivax ma-
laria antigen, VMP001, to the surfaces of lipid-coated PLGA
particles, and MPL has been incorporated into the lipid mem-
branes [47]. In the study PLGA particle surfaces were coated
with lipids composed of DOPC, DOPG, and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide].
The prolonged release of antigens delivered by PLGA
nanoparticles was shown to enhance the immune response to
the model OVA antigen [8]. PLGA nanoparticles provided an
OVA release profile that extended over 10 weeks and was
much slower than the release profile obtained from a lipo-
somal formulation. In line with the sustained release profile,
an OVAePLGA particulate vaccine formulation induced a
higher antibody titer compared to the liposome formulation 8
weeks after subcutaneous administration in mice.
The synthetic PLGA vaccine SEL-068 (Selecta Bioscience,
Inc., USA) is now in phase I clinical trials for the prevention of
nicotine addiction and relapse (http://www.selectabio.com).
SEL-068 was designed to facilitate smoking cessation and is
the first nano-vaccine to enter clinical trials. The SEL-068
formulation incorporates a universal peptide antigen for
eliciting T helper cell response and an immunostimulating
TLR agonist into the PLGA polymer matrix. Nicotine, a B cell
antigen, is covalently linked to the nanoparticle surfaces. No
dose-limiting systemic toxicities were observed in a repeat-
dose GLP safety and efficacy study in cynomolgus monkeys.
Other biodegradable polymers, including poly (ε-capro-
lactone) and polyanhydrides, have been tested for their utility
in vaccine delivery applications. The H1N1 hemagglutinin
antigen was incorporated into chitosan-coated poly-
caprolactone nanoparticles. Intranasal delivery of the chito-
sanepolycaprolactone nanocarriers containing H1N1
hemagglutinin was shown to produce serum IgG levels and
secretory IgA levels in nasal and lung lavage that were higher
than those produced following intranasal delivery of the sol-
uble antigen to Balb/c mice [48].
Polyanhydride nanocarriers have been tested as vaccine
delivery systems to take advantage of their biodegradable and
safety profiles. Polyanhydride nanoparticles containing Yersi-
nia pestis antigens were examined for intranasal vaccination
[49]. The recombinant protein F1eV was co-loaded with the
adjuvant MPL to induce the generation of F1eV-specific anti-
bodies detected 23 weeks post-vaccination. Polyanhydride
microparticles were shown to be taken up by DC cells and to
induce antigen-specific proliferation of both CD4þ and CD8þ
T cells [50].
Numerous polymeric nanoparticles have been designed to
physically entrap antigens within polymer matrices. Electro-
static polyplexes have also been tested for their utility in
delivering subunit antigens [51] or plasmid DNA vaccines
[52,53]. Hepatitis B surface antigen was loaded onto cationic L-poly lactic acidmicrospheres via the formation of electrostatic
complexes [51]. A single subcutaneous immunization with
HBsAg complexed onto the surfaces of cationic microspheres
was found to induce comparable levels of serum IgG re-
sponses and higher cellular immune responses as compared
to two injections of HBsAg with adjuvant alum in a mouse
model.
Cationic polymers have been used to form complexes with
negatively charged plasmid DNA vaccines. Deacylated
cationic polyethyleneimine was used to form complexes with
the human immunodeficiency virus (HIV) CN54gp140 antigen
[52]. Pulmonary administration of the polyplexes elicited an
immune response and protected the immunizedmice against
viral challenge. PEGylated poly [2-(N,N-dimethylamino)ethyl
methacrylate] was used to deliver HIV gag DNA vaccine [53].
Intranasal administration of the polyplexes was observed to
enhance the gag-specific serum IgG levels and IFN-g secreting
splenocytes in mice as compared to the naked DNA vaccine-
treated group.
Synthetic polymer-based vaccine delivery systems can
provide a sustained release profile for vaccine antigens over
prolonged periods of time. The release profilemay be tuned by
controlling the molecular weights of the synthetic polymers
and the encapsulation conditions. Relatively few biodegrad-
able and biocompatible synthetic polymeric delivery systems
have been tested to date, and the safety profiles of the biodeg-
radation products have not been extensively studied. Progress
in the field of biodegradable polymer development is antici-
pated to accelerate polymer-based vaccine delivery studies.
2.4. Natural biopolymer-based nanodelivery systems
Natural biopolymers, including chitosan and pullulan, have
been studied as vaccine or adjuvant delivery systems. Chito-
san is biocompatible, nontoxic, biodegradable, and provides a
cationic charge that may facilitate endocytosis. In the context
of vaccine delivery, chitosan displays valuable properties,
includingmucoadhesiveness and an adjuvanticity that acts by
promoting the maturation of DCs.
The mucoadhesiveness of chitosan has been exploited in
mucosal vaccine delivery formulations. A recent study
showed that an N-trimethyl chitosan nanocarrier carrying a
model antigen OVA provided prolonged residence in nasal
mucosa compared to PLGA nanoparticles bearing the same
antigen [54]. Whereas intramuscularly administered N-tri-
methyl chitosan-based vaccine formulations provided im-
mune responses that were comparable to those generated by
the PLGA-based vaccine, intranasally administered N-tri-
methyl chitosan-based vaccine formulations induced higher
antigen-specific secretory IgA levels compared to PLGA car-
riers. These results suggest the importance of mucoadhe-
siveness in vaccine carriers for enhancing the induction of
mucosal immunity.
Chitosan nanoparticles were studied as mucosal vaccine
delivery systems [55]. Chitosan nanoparticles that encapsu-
lated the hemagglutinin-split influenza virus were prepared
by ionically crosslinking the chitosan polymers in the pres-
ence of sodium tripolyphosphate. Two intranasal vaccination
doses of the hemagglutinin-split influenza virus entrapped in
chitosan nanoparticles induced higher systemic and mucosal
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vaccine prepared from the hemagglutinin-split influenza
virus alone in mice.
The intracellular fate of the HBsAg encapsulated in chito-
san nanoparticles has been examined [56]. The cellular fates
of the HBsAg and chitosan nanoparticles were followed by
fluorescently labeling the HBsAg and chitosan with Cy3 and
Cy5, respectively. The HBsAg-containing chitosan nano-
particles were found to be endocytosed by bone marrow-
derived DC, and the HBsAg was found to dissociate from the
nanoparticles 6 h after cellular uptake. The dissociation of
HBsAg from the chitosan nanoparticles was thought to result
from the chitosan matrix degradation in the lysosome.
Cholesteryl-conjugated pullulan polymer-based nanoscale
hydrogels were studied as potential vaccine vehicles [57]. A
non-toxic subunit fragment of the Clostridium botulinum type-
A neurotoxin BoHc/A was loaded into the nanogel and
administered intranasally. The viscosity of the nanogel pro-
moted the retention of BoHc/A in the nasal mucosal layer.
After release from the nanogel, BoHc/A was taken up by the
mucosal DCs. The intranasal nanogel formulations provided
high titers of the antigen-neutralizing serum IgG and antigen-
specific sIgA in the absence of additional mucosal adjuvants.
Synthetic and natural polymer hybrid vaccine delivery
systems have been investigated. For example, chitosan-
coated polycaprolactone nanoparticles were developed for
the intranasal delivery of the recombinant influenza A virus
(A/California/07/2009) H1N1 hemagglutinin protein [48]. About
66.5% of entrapped antigens were released from the nano-
particles over 63 days. A single intranasal immunization with
the antigen-loaded chitosan-coated polycaprolactone nano-
particles resulted in a total IgG response that exceeded the
response achieved after a booster intramuscular administra-
tion of the free subunit antigen solution in Balb/c mice.
2.5. Carbon-based nanodelivery systems
Carbon-based nanomaterials and carbon nanotubes in
particular were recently investigated as antigen delivery sys-
tems [58]. Carbon-based nanodelivery systems are insoluble,
non-degradable, andmimic bacteria in size and shape. Carbon
nanotubes are not intrinsically immunogenic, display a low
toxicity, are capable of carrying multiple antigens, and are
taken up rapidly by antigen-presenting cells. Such features
support the feasibility of using carbon nanotubes as antigen
carriers.
Zeinali and colleagues examined the utility of single-
walled carbon nanotubes (SWCNTs) in vaccine delivery sys-
tems [59]. A purified tuberculin protein derivative was loaded
onto a carboxyl group-functionalized SWCNT through cova-
lent binding. Following subcutaneous administration, the
antigeneSWCNT conjugate was found to stimulate the pro-
duction by Th1 cells of cytokines, such as IFN-g and IL-12, at
levels comparable to those generated through administration
of the conventional tuberculosis BCG vaccine.
A recent study reported the importance of carbon nano-
tube type on the induction of immunogenicity [60]. In the
study, a commercially available fungicide azoxystrobin was
loaded onto four types of carbon nanotube (short and single-
walled, short and multi-walled, long and single-walled, andlong andmulti-walled). The resulting immune responseswere
then compared. The short andmulti-walled carbon nanotubes
0.5 mm in length and 50 nm in diameter were found to provide
the highest anti-azoxystrobin IgG antibody titers in rabbits.
Carbonmagnetic nanoparticles were constructed to permit
the tracing of carbon-based vehicles [61]. Magnetic resonance
imaging data showed that magnetic nanoparticles 20e80 nm
in diameter were rapidly distributed to the spleen, followed by
the kidneys and the inguinal lymph nodes. The preferential
targeting of carbonmagnetic nanoparticles to DCswas used to
enrich DCs ex vivo using an externalmagnet. The biotinylated
model antigen hen egg lysozyme protein and the biotinylated
TLR ligand CpG were attached to avidin-coated carbon mag-
netic nanoparticles to improve the induction of T cell activa-
tion and antigen-specific IFN-g responses compared to the
free protein antigen.
The nanostructures of carbon-based materials were re-
ported to affect the antigen presentation process [62]. Gra-
phene oxide nanosheets (Fig. 1D) differed from C60 fullerenes
in its ability to promote antigen presentation to the T cells. C60
fullerenes stimulated MHC class I antigen presentation of
OVA, whereas graphene oxide suppressed antigen presenta-
tion by DCs. Moreover, unlike the C60 fullerenes, graphene
oxide reduced the immunoproteasomes in DCs.
Although most carbon-based vaccine delivery systems
have been tested through systemic administration, a recent
study examined the feasibility of using carbon nano-
particles for oral vaccine delivery [63]. Carbon nanoparticles
470 nm in diameter bearing 40e60 nm pores were synthe-
sized using silica as a template. Instead of loading the an-
tigens via surface adsorption, the model antigen, bovine
serum albumin, was encapsulated within the meso- and
macropores of the nanoparticles. The rigid structure of the
nanoparticles resisted destruction in the oral digestive tract
and appeared to protect the antigens from the harsh en-
vironments of the alimentary canal after oral delivery. In
this study, the IgG and cytokine immune responses elicited
by the oral bovine serum albumin entrapped in the porous
nanoparticles were comparable to those elicited by paren-
teral administration of bovine serum albumin with Freund's
adjuvant.
Carbon-based nanomaterial vaccine delivery systems are
relatively new and less well studied than other systems.
Several investigations have indicated the feasibility of carbon-
based systems for systemic or oral antigen delivery. Future
developments should demonstrate whether the lack of
biodegradability will promote or reduce the safety of a carbon-
based nano delivery system.3. Current & future developments
Nanotechnology-based vaccine delivery systems have been
developed to enhance the immunogenicity of a vaccine anti-
gen by modulating antigen delivery to the immune cells.
Nanocarrier formulations of vaccines offer the advantages of
co-delivery of antigen and immunomodulator [64]. Numerous
studies have reported enhanced immunogenicity of
nanocarrier-based vaccines upon co-delivery with an immu-
nomodulator. Single immunization of OVA and MPL co-
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 2 7e2 3 5 233formulated with the PLGA nanocarrier induced much higher
systemic and mucosal immune responses after oral delivery
than OVA alone [65]. Micelle formulations that include a PEG-
modified cationic polypeptide can co-deliver OVA and TLR3
agonists while increasing vaccine-induced antibody produc-
tion by more than a factor of 70 [66]. The subcutaneous
vaccination of pH-responsive micelle nanoparticles contain-
ing amphiphilic diblock copolymers conjugated to OVA and
CpG oligonucleotides displayed remarkably higher CD8þ T
cell responses compared with the free form or a physical
mixture [67].
In addition to the co-delivery of antigens and immuno-
modulators, modifying the surfaces of nanocarriers can
contribute to the delivery of antigens specifically to relevant
immune cells. Imiquimod (TLR7 agonist)-entrapped PLGA
nanocarriers were coated with a chitosan derivative (N,N,N-
trimethylated chitosan) to improve the protective response
generated by mucosal immunization [68]. Another chitosan
derivative, glycol chitosan, was decorated onto the surfaces of
PLGA nanoparticles for use in a nasal vaccination [69]. Glycol
chitosan-coated PLGA nanoparticles showed a lower clear-
ance rate and a higher local uptake in the nasal cavity
compared with chitosan-coated PLGA nanocarriers.
Multifunctional nanovaccines can significantly increase
the immune response generated by the target-specific, effec-
tive, and stable delivery of an antigen. However, the use of
many-component nanovaccines with complex structures can
increase production costs and complicate the manufacturing
process. Many nanovaccines have been manufactured in
small batches for research use [70]. Batch-to-batch variations
with respect to particle size, shape, and quality are critical
problems in the area of nanoparticle synthesis, and these
problems must be addressed during scale-up for clinical trial
testing [71,72]. Surface-modified nanoparticulate vaccines
require complicated synthesis procedures that can require
complex purification processes and high expenses. Scale-up
processes tend to be time-consuming for pharmaceutical ap-
plications. Self-assembled nanovaccine technologies would
be beneficial for reducing obstacles to the development of
industrial-scale manufacturing protocols.4. Conclusions
Nanotechnology platforms present promising strategies for
improving the immunogenicity of a vaccine antigen. Nano-
carriers that are useful for the formulation and delivery of
antigens and adjuvants offer many advantages over alterna-
tive adjuvant approaches, including improved stability, sus-
tained release kinetics, lower immunotoxicity, and targeting
to specific and selective immune cells. In addition, nano-
particles efficiently deliver antigens due to their nanoscale
size, solid form, ease of surface modification, and ability to
co-deliver antigens along with adjuvants. Although the ap-
plications of nanotechnologies for nanocarrier-based vaccine
delivery are currently in a nascent investigational stage, and
only a few products are being tested in clinical trials, these
vaccine delivery systems may potentially be used more
broadly for the prevention and treatment of infectious
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